Philadelphia-based Tarsa Therapeutics, which is developing an oral form of the peptide hormone called salmon calcitonin that helps prevent osteoporosis.
The company just raised $2 million, according to a regulatory filing. This is its first fundraise since 2014, when it raised $17 million.
Calcitonin has been available in injectable and intranasal forms for decades, but Tarsa’s reformulation allows for it to be taken orally. The once-per-day pill, called TBRIA, which has shown better bone reabsorption rates than controls in clinical study.
Following a Phase 3 trial for the drug’s efficacy in postmenopausal women, the company filed an NDA in October. The technology is licensed from Enteris Biopharma.